Washington Trust Advisors’s Moderna MRNA Stock Holding History

Washington Trust Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18	Closed	-$914	–	758
2026 Q1	$914	Buy	+18	New	+$840	﹤0.01%	662
2025 Q3	–	Sell	-35	Closed	-$966	–	707
2025 Q2	$966	Hold	35	–	–	﹤0.01%	625
2025 Q1	$992	Hold	35	–	–	﹤0.01%	629
2024 Q4	$1.46K	Hold	35	–	–	﹤0.01%	631
2024 Q3	$2.34K	Hold	35	–	–	﹤0.01%	629
2024 Q2	$4.16K	Hold	35	–	–	﹤0.01%	585
2024 Q1	$3.73K	Hold	35	–	–	﹤0.01%	600
2023 Q4	$3.48K	Hold	35	–	–	﹤0.01%	610
2023 Q3	$3.62K	Hold	35	–	–	﹤0.01%	587
2023 Q2	$4.25K	Hold	35	–	–	﹤0.01%	567
2023 Q1	$5.38K	Hold	35	–	–	﹤0.01%	592
2022 Q4	$6.29K	Hold	35	–	–	﹤0.01%	567
2022 Q3	$4K	Hold	35	–	–	﹤0.01%	757
2022 Q2	$5K	Hold	35	–	–	﹤0.01%	749
2022 Q1	$6K	Hold	35	–	–	﹤0.01%	790
2021 Q4	$9K	Buy	+35	New	+$10.2K	﹤0.01%	749

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Washington Trust Advisors's MRNA Position: Q2 2026 in Review

Washington Trust Advisors sold out of Moderna (MRNA) in Q2 2026, closing a stake of 18 shares — an estimated $914 sold.

Washington Trust Advisors first reported a position in MRNA in Q4 2021 and held it in 16 quarters. The position peaked at $9K in Q4 2021. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Washington Trust Advisors reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Washington Trust Advisors sold 18 Moderna shares in Q2 2026, an estimated $914.
Washington Trust Advisors first reported a position in Moderna in Q4 2021 and held it in 16 quarters.
Washington Trust Advisors's Moderna position peaked at $9K in Q4 2021.
784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Washington Trust Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.